

About the Study
This is a research study evaluating the safety of an investigational drug as well as how it is processed in the body. Participation will include frequent clinic visits, questionnaires, physical exams, and blood tests.
- The study assessments and study drug will be provided free of charge.
- Participation is voluntary.
- Choosing not to participate will not affect your regular medical care.
What happens during the study?
For each participant, the study could last up to 3 years in total.
More frequent visits to the study center are required early on. Visits will become less frequent later on in the study. There will be around 11 in-person visits at the study center during the first 16 weeks. A study participant will receive the investigational drug 9 times during this period.
In the second part of the study, which will last about 104 weeks, there will be 15 in-person visits:
- With 14 injections at the study center
- And possibly 11 self-injections at home.
- There will be a final in-person visit at the study center 20 weeks after the last injection of the investigational drug.
- The number of injections a study participant receives each time will depend on how much the person weighs.
- The investigational drug is given by injection just under the skin (in the fatty tissue just under the outer layer).
During the first part of the study (initial study treatment phase), the investigational drug will be given to study participants by staff at the study center. During the second part of the study (open-label extension), to reduce travel time to the study center, each study participant or caregiver may choose to receive training in how to give the injections at home. Approximately half of the injections will be given by staff at the study center.
While study participants will not receive any payment for participation in this study, reimbursement for study- related travel costs may be provided. Before any decision can be made about joining the study, the study team will explain everything in more detail, including the known risks and benefits. There will also be the opportunity to ask questions.
Assessments and tests during study visits may include:
Collection of personal and health data, such as age, sex, medical history, and current medications
Measurement of weight and height
Collection of a small amount of blood
Collection of a small amount of urine
Checking for any unexpected health issues or side effects after being given the investigational drug
Completing questionnaires to rate own health and effects of HS on well-being
Visual body checks for any visible health issues, listening to the heart and lungs, checking body temperature and blood pressure
Review of other medications taken since the previous study visit

Participation Criteria
You may be eligible to participate if you:
- Are between 12 to 17 years old, inclusive
- Have been diagnosed with hidradenitis suppurativa (HS) at least 6 months ago
- Have moderate to severe HS
- Have at least 5 inflammatory HS lesions
- Have HS affecting two or more different areas of the body
- Have tried a systemic antibiotic (pills, liquid, or IV) for HS in the past that did not work well
- Weigh at least 30 kg (about 66 pounds)
- Are willing to attend study visits and follow study instructions
You may not be eligible if you:
- Have a history of inflammatory bowel disease (IBD)
- Have active tuberculosis (TB) or untreated latent TB
- Have had serious or ongoing infections
- Have received certain medications for HS in the past
- Have participated in this same study before
- Have had recent severe depression, suicidal thoughts, or psychiatric hospitalization
- Are currently taking medications that are not allowed by the study
The study team will go through multiple other checks to confirm if the study is the right fit for anyone interested in participating.
Why join the BE AWARE Study?
Joining a clinical research study is a very personal and individual decision, so please take time to consider if this is the right choice. Any participant can stop study participation/withdraw at any time without having to give a reason.
Deciding not to take part will not affect any medical care now or in the future. However, study participation is incredibly valuable. The main goal of the study is to learn more about how the investigational drug affects young people like you/your child who have HS.
What are the potential risks and benefits of the BE AWARE Study?
Participants may not see any personal benefit from joining the BE AWARE Study. Before entering the study, more detailed information on what side effects can happen during the study will be discussed. Participants and caregivers should talk to the study doctor about any potential side effects of concern.
It is crucial to test HS drugs in children and teenagers living with this condition because:
- Young bodies can react differently to drugs compared to adults.
- Knowing the right dosage for different ages or body weights is important.
- It allows testing for safety and efficacy so treatments can be developed for all age groups.
- It helps to understand any unique side effects in younger people.
Important Notes
Always talk with your healthcare provider before joining a research study.
This study is not a guarantee of benefit.
Not everyone who applies will qualify.
Final eligibility is determined by the study team.
Contact Info
For more information about the study or to find the nearest site:
Recruiting Study Locations (US)
Arizona
Phoenix, AZ
For questions or comments, please contact the study coordinator for this location:
Cing Vung – vcing@usdermpartners.com
California
Roseville, CA
For questions or comments, please contact the study coordinator for this location:
Sandra Bello sandraclinicaltrials@gmail.com
Sacramento, CA
For questions or comments, please contact the study coordinator for this location:
Hasina Safi –
hasina@integrativeskinresearch.com
Florida
Miami, FL
For questions or comments, please contact the study coordinator for this location:
Patricia Di Taranto –
ped49@med.miami.edu
Kentucky
Franklin, KY
For questions or comments, please contact the study coordinator for this location:
Amy Steward –
asteward@equity-med.com
Michigan
Clarkston, MI
For questions or comments, please contact the study coordinator for this location:
Brianna Cole – bcole@docsdermgroup.com
Danielle Bartlett – dbartlett@docsdermgroup.com
Fort Gratiot, MI
For questions or comments, please contact the study coordinator for this location:
Camrynn Campbell – ccollinge@hamzavi.com
Alyson Campbell – ACampbell@hamzavi.com
Troy, MI
For questions or comments, please contact the study coordinator for this location:
Navya Kamath – nkamath@rev-research.com
New York
Brooklyn, NY
For questions or comments, please contact the study coordinator for this location: COMING SOON.
North Carolina
Chapel Hill, NC
For questions or comments, please contact the study coordinator for this location:
Michael Povelaitis –
michael_povelaitis@med.unc.edu
Ohio
Fairborn, OH
For questions or comments, please contact the study coordinator for this location:
Jessica Hong – jessica.hong@wright.edu
Texas
Arlington, TX
For questions or comments, please contact the study coordinator for this location:
Alicia Soulivong – alicias@acderm.com
Washington DC
Washington, DC
For questions or comments, please contact the study coordinator for this location:
Akosua Otoo – aotoo@childrensnational.org

